* duration of symptoms \>5 days * dyspnoea at rest * need for supplemental oxygen to maintain o2 saturation \>93% * solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms * patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment * decompensated liver cirrhosis * participation in another clinical trial * history of hypersensitivity to haematological derivatives * pregnancy or lactation, * ast/alt \>5 times the upper limit of normal or at baseline in patients with chronic liver disease * any condition that in the opinion of the investigator limits participation in the study. * patients who had received monoclonal antibodies against sars-cov-2

* duration of symptoms \>5 days * dyspnoea at rest * need for supplemental oxygen to maintain o2 saturation \>93% * solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms * patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment * decompensated liver cirrhosis * participation in another clinical trial * history of hypersensitivity to haematological derivatives * pregnancy or lactation, * ast/alt \>5 times the upper limit of normal or at baseline in patients with chronic liver disease * any condition that in the opinion of the investigator limits participation in the study. * patients who had received monoclonal antibodies against sars-cov-2

duration of symptoms >5 days dyspnoea at rest need for supplemental oxygen to maintain o2 saturation >93% solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment decompensated liver cirrhosis participation in another clinical trial history of hypersensitivity to haematological derivatives pregnancy or lactation, ast/alt >5 times the upper limit of normal or at baseline in patients with chronic liver disease any condition that in the opinion of the investigator limits participation in the study. patients who had received monoclonal antibodies against sars-cov-2

duration of symptoms >5 days dyspnoea at rest need for supplemental oxygen to maintain o2 saturation >93% solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment decompensated liver cirrhosis participation in another clinical trial history of hypersensitivity to haematological derivatives pregnancy or lactation, ast/alt >5 times the upper limit of normal or at baseline in patients with chronic liver disease any condition that in the opinion of the investigator limits participation in the study. patients who had received monoclonal antibodies against sars-cov-2